| Allogene Therapeutics (ALLO) Loses -31.94% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner |
Allogene Therapeutics (ALLO) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term. |
zacks.com |
2025-05-15 14:36:04 |
Czytaj oryginał (ang.) |
| Allogene's Q1 Earnings In Line With Estimates, Sales Nil |
ALLO's first-quarter earnings match estimates. Devoid of marketed products, the company records nil sales in the quarter. |
zacks.com |
2025-05-14 11:30:36 |
Czytaj oryginał (ang.) |
| Allogene Therapeutics, Inc. (ALLO) Q1 2025 Earnings Call Transcript |
Allogene Therapeutics, Inc. (NASDAQ:ALLO ) Q1 2025 Earnings Conference Call May 13, 2025 5:00 PM ET Company Participants Christine Cassiano - EVP, Chief Corporate Affairs & Brand Strategy Officer David Chang - Co-Founder, President, CEO & Director Zachary Roberts - EVP, Research & Development & CMO Geoff Parker - EVP & CFO Conference Call Participants Michael Yee - Jefferies Tyler Van Buren - TD Cowen Biren Amin - Piper Sandler Brian Chang - JPMorgan Matthew Biegler - Oppenheimer Samantha Semenkow - Citi John Newman - Canaccord Genuity William Pickering - Bernstein Operator Hello. Thank you for standing by, and welcome to Allogene Therapeutics First Quarter and 2025 Conference Call. |
seekingalpha.com |
2025-05-14 02:47:15 |
Czytaj oryginał (ang.) |
| Allogene Therapeutics Reports First Quarter 2025 Financial Results and Business Update |
Pivotal Phase 2 ALPHA3 Trial with Cemacabtagene Ansegedleucel (Cema-Cel) in First Line (1L) Consolidation in Large B-Cell Lymphoma (LBCL) Nearly 50 Sites Activated Across U.S. with Strong Enthusiasm from Investigators Lymphodepletion Selection and Futility Analysis Shifted to 1H 2026 in Part Due to Site-Related Factors that Impacted Expected Pace of Screening Immediately Following Site Activation Over 250 Patients Consented for MRD Screening to Date, with Nearly Half in the Last Three Months and Awaiting Completion of 1L Treatment as Earliest Activated Sites Build Momentum International Expansion of ALPHA3 Trial to Begin with Site Activations in Canada in Q2 2025 Phase 1 RESOLUTION Trial with ALLO-329 in Autoimmune Disease (AID) RESOLUTION Basket Trial in Rheumatology on Track for Mid-2025 Start Proof-of-Concept Data Moved to 1H 2026 to Enable Inclusion of Both Biomarker and Clinical Data Phase 1 TRAVERSE Trial with ALLO-316 in Renal Cell Carcinoma (RCC) Updated Phase 1 Trial Results Will be Featured in an Oral Presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting Presentation to Highlight Meaningful Clinical Responses from the Phase 1B Expansion Cohort and Key Translational Findings, Including Ability for CD70 Dagger® Technology to Drive Robust CAR T Cell Expansion and Persistence Ended Q1 2025 with $335.5 Million in Cash, Cash Equivalents and Investments Cost Realignment and Strategic Prioritization Will Extend Cash Runway Into 2H 2027 Spend Focused on Advancing the Cema-Cel/ALPHA3 and ALLO-329/RESOLUTION Clinical Trials to Key Inflection Points Targeted Reductions in Manufacturing Operations Provide Key Savings While Preserving Core Capabilities Conference Call and Webcast Scheduled for Today at 2:00 PM PT/5:00 PM ET SOUTH SAN FRANCISCO, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today provided corporate updates and reported financial results for the quarter ended March 31, 2025. |
globenewswire.com |
2025-05-13 20:05:00 |
Czytaj oryginał (ang.) |
| Allogene Therapeutics to Report First Quarter 2025 Financial Results and Provide Business Update |
Conference Call and Webcast Scheduled for May 13, 2025 at 2:00 p.m. PT/5:00 p.m. |
globenewswire.com |
2025-05-06 12:30:00 |
Czytaj oryginał (ang.) |
| Allogene Therapeutics to Present Updated ALLO-316 Clinical Results in Kidney Cancer in Oral Presentation and ALPHA3 Trial-in-Progress Poster for Cema-Cel at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting |
SOUTH SAN FRANCISCO, Calif., April 23, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced that it will present updated data from the completed Phase 1 TRAVERSE trial of ALLO-316 in an oral presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 29-June 2 in Chicago, Illinois. The trial evaluated ALLO-316 in patients with advanced or metastatic renal cell carcinoma (RCC) who had progressed following immune checkpoint inhibitor and VEGF-targeted therapies. In addition, a trial-in-progress poster is also being presented to highlight the ongoing pivotal Phase 2 ALPHA3 trial, which is evaluating cemacabtagene ansegedleucel (cema-cel) as part of first-line (1L) treatment for patients with large B-cell lymphoma (LBCL). |
globenewswire.com |
2025-04-23 14:12:00 |
Czytaj oryginał (ang.) |
| FDA Grants Three Fast Track Tags to Allogene's Autoimmune Disease Drug |
The FDA's fast track designations will facilitate rapid development and expedited review of ALLO's autoimmune disease candidate. |
zacks.com |
2025-04-08 11:50:33 |
Czytaj oryginał (ang.) |
| Allogene Granted Three U.S. FDA Fast Track Designations (FTD) for ALLO-329, a Next-Generation Dual-Targeted CD19/CD70 Allogeneic CAR T, for the Treatment of Lupus, Myositis and Scleroderma |
SOUTH SAN FRANCISCO, Calif., April 07, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced that ALLO-329, an investigational dual-targeted CD19/CD70 allogeneic CAR T, has received three Fast Track Designations (FTD) from the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with: |
globenewswire.com |
2025-04-07 12:30:00 |
Czytaj oryginał (ang.) |
| Allogene's Q4 Loss Narrower Than Expected, Revenues Nil |
ALLO's fourth-quarter earnings beat estimates. Devoid of marketed products, the company records no sales in the quarter. |
zacks.com |
2025-03-14 10:56:04 |
Czytaj oryginał (ang.) |
| Allogene Therapeutics, Inc. (ALLO) Q4 2024 Earnings Call Transcript |
Allogene Therapeutics, Inc. (NASDAQ:ALLO ) Q4 2024 Earnings Conference Call March 13, 2025 5:00 PM ET Company Participants Christine Cassiano - EVP, Chief Corporate Affairs & Brand Strategy Officer David Chang - Co-Founder, President, CEO & Director Zachary Roberts - EVP, Research & Development & CMO Geoff Parker - EVP & CFO Conference Call Participants Tyler Van Buren - TD Cowen Michael Yee - Jefferies Brian Cheng - JPMorgan Sami Corwin - William Blair Jack Allen - Baird Biren Amin - Piper Sandler John Newman - Canaccord Genuity Asthika Goonewardene - Truist Matthew Biegler - Oppenheimer Shelby Tucker - RBC Capital Markets Samantha Semenkow - Citi Carolina Ibanez-Ventoso - Stifel Laura Prendergast - Raymond James Operator Hello. Thank you for standing by, and welcome to Allogene Therapeutics Fourth Quarter and Full Year 2024 Conference Call. |
seekingalpha.com |
2025-03-14 01:56:56 |
Czytaj oryginał (ang.) |
| Allogene Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Update |
SOUTH SAN FRANCISCO, Calif., March 13, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today provided corporate updates and reported financial results for the quarter and full year ended December 31, 2024. |
globenewswire.com |
2025-03-13 18:02:00 |
Czytaj oryginał (ang.) |
| Allogene Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update |
SOUTH SAN FRANCISCO, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced that it will report the fourth quarter and full year 2024 financial results and provide a business update on March 13, 2025, after the close of the market. The announcement will be followed by a live audio webcast and conference call at 2:00 p.m. PT/5:00 p.m. ET. |
globenewswire.com |
2025-03-03 10:30:00 |
Czytaj oryginał (ang.) |
| Allogene: Assessing The Pipeline, Competitive Landscape, And Opportunities |
Allogene Therapeutics is developing allogeneic CAR-T cells for cancer and autoimmune diseases, offering off-the-shelf therapies that reduce costs and treatment times. Cema-cel, Allogene's leading product, shows promise in first-line treatment of large B-cell malignancies, with significant revenue potential and positive clinical trial results. Allogene's financial health is stable, with a cash runway until Q1, 2026, and the company is rated a "Buy" for long-term, high-risk-tolerant investors. |
seekingalpha.com |
2025-02-26 12:52:02 |
Czytaj oryginał (ang.) |
| Allogene Therapeutics Announces Participation in March Investor Conference |
SOUTH SAN FRANCISCO, Calif., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced that it will participate in one upcoming investor conference in March. |
globenewswire.com |
2025-02-26 10:30:00 |
Czytaj oryginał (ang.) |
| Allogene Therapeutics Expands Strategic Partnership with Foresight Diagnostics to Advance Joint Development Activities Outside the US Across Europe, UK, Canada, and Australia |
SOUTH SAN FRANCISCO, Calif., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced an expanded strategic collaboration with Foresight Diagnostics, Inc. to include the development of Foresight's minimal residual disease (MRD) assay as a companion diagnostic to identify patients with large B-cell lymphoma (LBCL) for treatment with cemacabtagene ansegedleucel (cema-cel). |
globenewswire.com |
2025-02-25 18:10:00 |
Czytaj oryginał (ang.) |
| Allogene Therapeutics: Disrupting CAR-T With A Scalable Model |
Allogene Therapeutics: Disrupting CAR-T With A Scalable Model |
seekingalpha.com |
2025-02-25 00:53:56 |
Czytaj oryginał (ang.) |
| Allogene Therapeutics Announces Publication of Durable Response Data from Phase 1 ALPHA/ALPHA2 Trials of the Allogeneic CAR T Cemacabtagene Ansegedleucel/ALLO-501 in Relapsed/Refractory Large B-Cell Lymphoma in the Journal of Clinical Oncology |
SOUTH SAN FRANCISCO, Calif., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced the publication of data from its Phase 1 ALPHA and ALPHA2 clinical studies of cemacabtagene ansegedleucel (cema-cel; formerly ALLO-501/A) in relapsed/refractory (R/R) large B-cell lymphoma (LBCL) as a Rapid Communication in the Journal of Clinical Oncology. These results represent the largest dataset of LBCL patients treated with an allogeneic CAR T product and, with a minimum of two years of follow-up, the longest follow-up to date. |
globenewswire.com |
2025-02-13 18:30:00 |
Czytaj oryginał (ang.) |
| Allogene Therapeutics Secures U.S. FDA IND Clearance for ALLO-329, Advancing its Next-Generation Allogeneic CAR T into Autoimmune Diseases |
SOUTH SAN FRANCISCO, Calif., Jan. 28, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for a rheumatology basket study of ALLO-329, an investigational allogeneic CAR T product. |
globenewswire.com |
2025-01-28 10:30:00 |
Czytaj oryginał (ang.) |
| 3 Beaten-Down Biotech Stocks to Buy for a Turnaround in 2025 |
Here we present three biotech stocks, ALLO, DAWN and IMCR, which took a beating in 2024 but have upside potential for 2025. |
zacks.com |
2024-12-26 16:10:23 |
Czytaj oryginał (ang.) |
| Allogene Therapeutics (ALLO) Upgraded to Buy: What Does It Mean for the Stock? |
Allogene Therapeutics (ALLO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. |
zacks.com |
2024-12-26 15:01:22 |
Czytaj oryginał (ang.) |
| 3 Under-$10 Drug Stocks Wall Street Analysts Recommend Buying |
We present three small biotech stocks, which according to Wall Street analysts, have upside potential for 2025. |
zacks.com |
2024-12-24 10:50:25 |
Czytaj oryginał (ang.) |
| Allogene Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference |
SOUTH SAN FRANCISCO, Calif., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced that David Chang, M.D., Ph.D., President, Chief Executive Officer and Co-Founder of Allogene, will present at the 43rd Annual J.P. Morgan Healthcare Conference at the Westin St. Francis in San Francisco. |
globenewswire.com |
2024-12-16 10:30:00 |
Czytaj oryginał (ang.) |
| Allogene Therapeutics Acknowledges the Passing of Founding Board Member David Bonderman |
SOUTH SAN FRANCISCO, Calif., Dec. 12, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today acknowledged the passing of founding board member, David Bonderman. David died at the age of 82, surrounded by his family. |
globenewswire.com |
2024-12-12 10:30:00 |
Czytaj oryginał (ang.) |
| Allogene Therapeutics Loses 23% Year to Date: How to Play the Stock? |
The dip in ALLO's share price can be attributed to strategic changes in its pipeline, which delayed bringing its lead drug to market by at least two years. |
zacks.com |
2024-12-02 16:20:34 |
Czytaj oryginał (ang.) |
| Allogene Therapeutics (ALLO) Upgraded to Buy: Here's Why |
Allogene Therapeutics (ALLO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. |
zacks.com |
2024-11-25 15:01:23 |
Czytaj oryginał (ang.) |
| Allogene Therapeutics Announces Participation in December Investor Conferences |
SOUTH SAN FRANCISCO, Calif., Nov. 19, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced that it will participate in two upcoming investor conferences in December. The Company is also announcing that the presentation time for the upcoming Jefferies London Healthcare conference on November 20, 2024 has changed. |
globenewswire.com |
2024-11-19 10:30:00 |
Czytaj oryginał (ang.) |
| Allogene Therapeutics Presents Preclinical Data for ALLO-329, an Allogeneic CD19/CD70 Dual CAR T for the Treatment of Autoimmune Disease at the American College of Rheumatology (ACR) Convergence |
SOUTH SAN FRANCISCO, Calif., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced preclinical data for ALLO-329, an investigational allogeneic CD19/CD70 dual CAR T cell therapy being evaluated as a treatment for autoimmune diseases. The data, presented at the American College of Rheumatology (ACR) Convergence 2024, demonstrate the potential of ALLO-329 to specifically address key challenges associated with current autologous CAR T cell therapies in development for patients with autoimmune disease and highlights the promise of an allogeneic CAR T to reset the immune system. |
globenewswire.com |
2024-11-18 10:30:00 |
Czytaj oryginał (ang.) |
| Allogene's Q3 Loss Narrower Than Expected, Sales Nil |
ALLO's third-quarter earnings beat estimates. Devoid of marketed products, management records no sales in the quarter. |
zacks.com |
2024-11-08 13:15:20 |
Czytaj oryginał (ang.) |
| Allogene Therapeutics, Inc. (ALLO) Q3 2024 Earnings Call Transcript |
Allogene Therapeutics, Inc. (NASDAQ:ALLO ) Q3 2024 Results Conference Call November 7, 2024 5:00 PM ET Company Participants Christine Cassiano - Chief Corporate Affair and Brand Strategy Officer David Chang - President and Chief Executive Officer Zachary Roberts - EVP of Research and Development and Chief Medical Officer Geoff Parker - Chief Financial Officer Conference Call Participants Michael Yee - Jefferies Jack Allen - Baird Biren Amin - Piper Sandler John Newman - Canaccord Genuity Luca Issi - RBC Capital Samantha Semenkow - Citi Matthew Biegler - Oppenheimer Brooke Schuster - William Blair William Pickering - Bernstein Laura Prendergast - Raymond James Operator Hello, and thank you for standing by. Welcome to Allogene Therapeutics' Third Quarter 2024 Conference Call. |
seekingalpha.com |
2024-11-07 22:59:01 |
Czytaj oryginał (ang.) |
| Allogene Therapeutics Reports Third Quarter 2024 Financial Results and Business Update |
SOUTH SAN FRANCISCO, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today provided corporate updates and reported financial results for the quarter ended September 30, 2024. |
globenewswire.com |
2024-11-07 18:02:00 |
Czytaj oryginał (ang.) |
| Allogene Therapeutics Announces Positive Phase 1 Data Demonstrating the Potential of ALLO-316 in Heavily Pretreated Patients with Advanced Renal Cell Carcinoma at SITC and IKCS |
SOUTH SAN FRANCISCO, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, will concurrently present new data from the Phase 1 TRAVERSE trial in an oral presentation at the 2024 International Kidney Cancer Symposium (IKCS) and a poster session at The Society for Immunotherapy of Cancer's (SITC) Annual Meeting. The trial evaluates ALLO-316, the Company's first AlloCAR T product candidate for the potential treatment of solid tumors. The ongoing Phase 1 TRAVERSE trial is enrolling patients with advanced or metastatic renal cell carcinoma (RCC) who have progressed following treatment with an immune checkpoint inhibitor and VEGF-targeting therapy. These presentations highlight compelling evidence of CAR T activity and anti-tumor efficacy in 26 patients with RCC tumors known to be CD70 positive who were evaluable for efficacy outcomes. |
globenewswire.com |
2024-11-07 12:00:00 |
Czytaj oryginał (ang.) |
| Allogene Therapeutics to Present New Data Demonstrating the Potential of ALLO-316 in Heavily Pretreated Adult Patients with CD70 Positive Advanced Renal Cell Carcinoma (RCC) at the International Kidney Cancer Symposium (IKCS) and Society for Immunotherapy of Cancer (SITC) Annual Meeting |
SOUTH SAN FRANCISCO, Calif., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced that it will present new data from the ongoing Phase 1 TRAVERSE trial at the 2024 International Kidney Cancer Symposium (IKCS) and the Society for Immunotherapy of Cancer's (SITC) annual meeting. The trial evaluates ALLO-316, the Company's first AlloCAR T product candidate for the potential treatment of solid tumors. These presentations will highlight data from 26 heavily pretreated patients with CD70 positive renal cell carcinoma (RCC) and will include details on the diagnostic and treatment algorithm used to mitigate treatment-associated hyperinflammatory response seen in some patients. The ongoing Phase 1 data supported the U.S. Food and Drug Administration's (FDA) October 2024 decision to grant Regenerative Medicine Advanced Therapy (RMAT) designation for ALLO-316 based on clinical data from the TRAVERSE trial indicating its to address the unmet need for adult patients with advanced or metastatic CD70 positive RCC who have failed multiple standard RCC therapies, including an immune checkpoint inhibitor and a VEGF-targeting therapy. |
globenewswire.com |
2024-11-05 11:10:00 |
Czytaj oryginał (ang.) |
| Will Allogene Therapeutics (ALLO) Report Negative Earnings Next Week? What You Should Know |
Allogene Therapeutics (ALLO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
zacks.com |
2024-10-31 13:06:22 |
Czytaj oryginał (ang.) |
| Allogene Therapeutics to Report Third Quarter 2024 Financial Results and Provide Business Update |
SOUTH SAN FRANCISCO, Calif., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced that it will report third quarter 2024 financial results and provide a business update on November 7, 2024, after the close of the market. The announcement will be followed by a live audio webcast and conference call at 2:00 p.m. PT/5:00 p.m. ET. |
globenewswire.com |
2024-10-30 10:30:00 |
Czytaj oryginał (ang.) |
| Allogene Therapeutics (ALLO) Stock Drops Over 5% Amid Market Activity |
Allogene Therapeutics, Inc. (ALLO, Financial) saw a significant drop in its stock price, falling 5.06% to $2.54 per share. The trading volume reached 1.41 million shares, with a turnover rate of 0.67% and a volatility of 4.49%. |
gurufocus.com |
2024-10-02 20:11:52 |
Czytaj oryginał (ang.) |
| Poseida: Interim P-BCMA-ALLO1 Data Bodes Well For Phase 1B Advancement |
Positive interim results released from phase 1/1b study using P-BCMA-ALLO1 for the treatment of patients with relapsed/refractory Multiple Myeloma. The global multiple myeloma market is projected to reach $44.22 billion by 2032. Interim data update for use of P-CD19CD20-ALLO1 in ongoing phase 1 study targeting patients with B-cell malignancies expected in the 2nd half of 2024 pending coordination with Roche. |
seekingalpha.com |
2024-09-30 15:47:50 |
Czytaj oryginał (ang.) |
| Allogene Therapeutics Announces Participation in the Goldman Sachs Cell Therapy Day Conference |
SOUTH SAN FRANCISCO, Calif., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced that it will participate in panel focused on innovations in the allogeneic cell therapy landscape during the Goldman Sachs Cell Therapy Day on October 1, 2024 in New York. |
globenewswire.com |
2024-09-30 12:30:00 |
Czytaj oryginał (ang.) |
| ALLO Communications Lays Foundation for Groundbreaking Business and Residential Experiences Over 50G PON Delivered With the Calix Broadband Platform |
SAN JOSE, Calif.--(BUSINESS WIRE)---- $CALX #calix--Today, Calix, Inc. (NYSE: CALX) reaffirmed the power of its cloud-and-software broadband platform to enable customers to simplify their business, innovate for their subscribers, and grow value for themselves and their communities. Supported by a trusted 15-year partnership, last week ALLO Communications and Calix conducted a 50G PON trial within the ALLO production network in Lincoln, Nebraska. The introduction of 50G PON on the Calix Broadband Platform will e. |
businesswire.com |
2024-09-24 19:00:00 |
Czytaj oryginał (ang.) |